Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
1 - 10 of 74
- Druglike FAPIs with maximal target residence time: chemical discovery and biological characterization.From1 Jan 2024 → TodayFunding: IOF - technology concept exploration
- Potent intra-tumoral autophagy blocking with kinase PROTACs and inhibitors.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Cell-type specific delivery of autophagy inducers as a strategy to address localized autophagy impairment in diseaseFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Directed optimization of highly selective DPP9 inhibitors for chemical biology and translational research.From1 Nov 2023 → TodayFunding: FWO fellowships
- Characterization and validation of novel autophagy inducers identified via high-throughput screening: a therapeutic option for the treatment of advanced atherosclerosis.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- AUTAC- and PROTAC-mediated degradation of DPP9 to induce pyroptosis: a novel treatment strategy in acute myeloid leukemia.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure (PaCaNano).From1 Sep 2023 → TodayFunding: FWO research project (including WEAVE projects)
- OncoProToolsFrom1 Jun 2023 → TodayFunding: BOF - projects
- DPP9 degradation-induced pyroptosis for treatment of acute myeloid leukemia (DPP9-TACDrug).From1 Apr 2023 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Diagnostic and theranostic targeting of fibroblast activation protein (FAP) with goed nanoparticles decorated with FAPIs and FAPI fragments.From1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 128
- Design and synthesis of selective DPP9 inhibitors(2024)
Authors: Siham Benramdane, Pieter Van Der Veken, Hans De Winter
Number of pages: 232 - Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics(2023)
Authors: Marcel Martin, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Joni De Loose, Emile Verhulst, Ingrid De Meester, Pieter Van Der Veken, Frank Roesch
Pages: 1 - 25 - Next generation fibroblast activation protein (FAP) targeting PET tracers(2023)
Authors: Christian B.M. Poulie, Vladimir Shalgunov, Filipe Elvas, Yentl Van Rymenant, Euy-Sung Moon, Umberto Maria Battisti, Joni De Loose, Ingrid De Meester, Frank Rösch, Pieter Van Der Veken, et al.
Pages: 1 - 10 - From PERK to RIPK1(2023)
Authors: Camilla Scarpellini, Sophie Valembois, Kenneth Goossens, Mike Vadi, Caroline Lanthier, Greta Klejborowska, Pieter Van Der Veken, Hans De Winter, Mathieu J.M. Bertrand, Koen Augustyns
Pages: 1 - 15 - Characterization of structurally diverse ¹⁸F-labeled d-TCO derivatives as a PET probe for bioorthogonal pretargeted imaging(2023)
Authors: Karuna Adhikari, Christel Vangestel, Pieter Van Der Veken, Sigrid Stroobants, Filipe Elvas, Koen Augustyns
Pages: 38252 - 38262 - Design, synthesis and evaluation of novel activity-based probes and inhibitors for trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Koen Augustyns, Pieter Van Der Veken
Number of pages: 289 - Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Lisse Decraecker, Valerie Cacheux, Irena Zeiburlina, Michelle De bruyn, Louise Battut, Carlos Moreno Cinos, Davide Ceradini, Eric Espinosa, Gilles Dietrich, et al.
Pages: 1 - 17 - Highly selective inhibitors of dipeptidyl peptidase 9 (DPP9) derived from the clinically used DPP4-inhibitor vildagliptin(2023)
Authors: Siham Benramdane, Joni De Loose, Nicolò Filippi, Margarida Florindo Espadinha, Olivier Beyens, Yentl Van Rymenant, Laura Dirkx, Murat Bozdag, Koen Augustyns, Guy Caljon, et al.
Pages: 12717 - 12738 - Vildagliptin‐derived dipeptidyl peptidase 9 (DPP9) inhibitors(2022)
Authors: Siham Benramdane, Joni De Loose, Olivier Beyens, Yentl Van Rymenant, Gwendolyn Vliegen, Koen Augustyns, Hans De Winter, Ingrid De Meester, Pieter Van Der Veken
Pages: 1 - 16 - Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients(2022)
Authors: An Bracke, Emilie De Hert, Michelle De bruyn, Karen Claesen, Gwendolyn Vliegen, Alexandra Vujkovic, Lida van Petersen, Fien De Winter, An Hotterbeekx, Isabel Brosius, et al.
Pages: 4 - 11
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)